However, despite the availability of numerous drugs such as statins to lower lipids, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers to control blood pressure, orlistat to reduce weight gain (Wilding, 2018), and a range of insulin-sensitizing drugs such as metformin, sulfonylureas, glitazones, gliptins, α-glucosidase inhibitors, and sodium-glucose transporter-2 inhibitors, for many diabetic patients the inevitable slide toward heart disease, renal failure, neuropathy and diabetic blindness continues unabated, leading to increased morbidity and mortality. Here, ACE is linked to Renal insufficiency.